DR info

臨床試験数 : 5 / 薬物数 : 11 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 35

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Abacavir (ABC)
   University of Edinburgh
      2022   Phase 2   NCT04731103   United Kingdom;
Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)
   University of Edinburgh
      2022   Phase 2   NCT04731103   United Kingdom;
Baricitinib
   Adeline Vanderver, MD
      2019   Phase 2   NCT03921554   United States;
   Eli Lilly and Company
      2020   Phase 2/Phase 3   NCT04517253   Japan;
      2007   -   NCT01724580   United Kingdom;United States;
LY3009104
   Eli Lilly and Company
      -   Phase 2   EUCTR2015-003424-31-GB   France;United Kingdom;United States;
Lamivudine (3TC)
   University of Edinburgh
      2022   Phase 2   NCT04731103   United Kingdom;
Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir
   Assistance Publique - Hôpitaux de Paris
      2015   Phase 2   NCT02363452   France;
Tenofovir (TDF) and Emtricitabine (FTC)
   Children's Hospital of Philadelphia
      2022   Phase 1/Phase 2   NCT03304717   United States;